Table 4. NF-κB, TGF-β3 and iNOS immunoreactivity at two and six weeks in the control, V5 (Vardenafil 5 mg) and V10 (Vardenafil 10 mg) groups.
| 2nd week | 6th week | p value | |
|---|---|---|---|
| Mean±SE | Mean±SE | ||
| NF-κB | |||
| Control group | 94.00±8.72 | 70.00±12.25 | 0.149 |
| V5 group | 66.67±10.85 | 65.00±21.16 | 0.971 |
| V10 group | 36.67±6.67** | 55.00±8.54 | 0.110 |
| p value | 0.0007 | 0.820 | |
| TGF-β3 | |||
| Control group | 206.00±8.94 | 120.00±20.0† | 0.008 |
| V5 group | 275.00±9.22** | 83.33±16.67† | 0.002 |
| V10 group | 288.33±8.33** | 75.00±20.45† | 0.002 |
| p value | <0.0001 | 0.284 | |
| iNOS | |||
| Control group | 76.00±10.30 | 100.00±22.36 | 0.674 |
| V5 group | 125.00±7.64* | 87.50±22.13 | 0.335 |
| V10 group | 141.67±9.46** | 63.33±17.26† | 0.002 |
| p value | 0.0001 | 0.188 | |
| NF-kB: Nuclear factor kappa B; TGF-b3: Transforming growth factor-b3; iNOS: Inducible nitric oxide synthase; H-SCORE data are presented as mean ± standard error mean; * p<0.01 and ** p<0.001 vs control group; † p<0.01 vs 2nd week group. | |||